I think its possible that the plan was, from the start, to try and get on the Naz ahead of Top-Line....no way to know though.  I'm figuring the company needed to put some checks in some boxes submitting an application in any case regardless of the timing....with the biggest check maybe being improving the company's incredibly weak cash position. 

As things stand right now I believe the company owes more to Third Line than they have in cash....which I'm thinking would probably make a Naz application a non-starter.  Here's what I'm thinking may have been the plan.

1- Get to 250 MACE in order to start wrapping up the trial.

2- Arrange a financing/offering to cash up in order to qualify for listing on the Naz.

3- After attaining the listing announce top-line results.

If the trial had wrapped up in Janary some time, then perhaps a share offering would have come in February.  Its a moot point in any case....250 MACE was announced April 18th, with Top-Line projected to be out in 2-4 months.  This offering and the resultant raise should be wrapped up I'm guessing in the next week or two.....let's say June 14th to give the company some wiggle room.

Continuing with the hypothetical let's say they apply to the Nas on June 17th and get approved with listing and the start of trading taking just a month, when Stellar Biotech went from the Venture/OTC to the Nas I don't even think it took that long.  We'll say trading starts July 22nd, and then Top-Line comes out July 24th.....

It strikes me that this could have possibly been the plan all along.....but the clock didn't start ticking and the dominoes didn't start falling until 250 Events were reached.  

Now to wait and see if this share offering goes through and how much (assuming its not withdrawn, which I guess is still theoretically possible)....how much is raised.  Then we can speculate if Resverlogix would qualify for a listing in the first place....